Pediatric Studies Of Difficult-To-Treat Cancers To Get Advisory Cmte. Review

GlaxoSmithKline's Votrient (pazopanib), Genentech's vismodegib and two investigational drugs will be the subjects for the Pediatric Oncology Subcommittee of FDA's Oncologic Drugs Advisory Committee Nov. 1.